A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K
- PMID: 520655
- DOI: 10.1177/030006057900700608
A multicentre study examining the substitution of Trasidrex for the free combination of Slow-Trasicor and Navidrex-K
Abstract
A multicentre, open study of general practice patients with essential hypertension who were currently being treated with oxprenolol and cyclopenthiazide was undertaken in which the patients were transferred to Trasidrex for 12 weeks. Weight, blood pressure, heart rate and side-effects were assessed pre-trial and at 4-week intervals. A global assessment was also made at the same time intervals. The mean serum potassium remained virtually unchanged after 12 weeks treatment with Trasidrex. Blood pressure control was marginally improved during the study and it is thought possible that better patient compliance might explain this. Trasidrex was tolerated equally as well as the free combination.
Similar articles
-
Trasidrex (a fixed combination of slow Trasicor 16o mg and Navidrex 0.25mg) in the treatment of hypertension: a multicentre clinical trial in general practice.J Int Med Res. 1978;6(6):494-8. doi: 10.1177/030006057800600615. J Int Med Res. 1978. PMID: 720740
-
A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice.J Int Med Res. 1981;9(5):315-8. doi: 10.1177/030006058100900503. J Int Med Res. 1981. PMID: 7028531 Clinical Trial. No abstract available.
-
Oxprenolol slow-release with cyclopenthiazide KCl in the treatment of essential hypertension. A multicentre general practice study.S Afr Med J. 1981 Jun 13;59(25):893-9. S Afr Med J. 1981. PMID: 7015537 Clinical Trial.
-
Oxprenolol slow-release with cyclopenthiazide-KCl compared with methyldopa in the treatment of essential hypertension. A multicentre general practice trial.S Afr Med J. 1978 Nov 18;54(21):860-4. S Afr Med J. 1978. PMID: 371021 Clinical Trial.
-
Fixed dose combination therapy in the treatment of hypertension.J Hum Hypertens. 2002 Feb;16(2):75-8. doi: 10.1038/sj.jhh.1001312. J Hum Hypertens. 2002. PMID: 11850763 Review. No abstract available.
Cited by
-
Effectiveness of fixed-dose combination therapy in hypertension: systematic review and meta-analysis.Arch Med Sci. 2018 Aug;14(5):1125-1136. doi: 10.5114/aoms.2018.77561. Epub 2018 Aug 13. Arch Med Sci. 2018. PMID: 30154897 Free PMC article. Review.
-
Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.Vasc Health Risk Manag. 2012;8:371-80. doi: 10.2147/VHRM.S28359. Epub 2012 Jun 11. Vasc Health Risk Manag. 2012. PMID: 22745561 Free PMC article. Review.
-
Current perspectives on combination therapy in the management of hypertension.Integr Blood Press Control. 2013 Jun 17;6:69-78. doi: 10.2147/IBPC.S33985. Print 2013. Integr Blood Press Control. 2013. PMID: 23837009 Free PMC article.
-
Free versus Fixed Combination Antihypertensive Therapy for Essential Arterial Hypertension: A Systematic Review and Meta-Analysis.PLoS One. 2016 Aug 22;11(8):e0161285. doi: 10.1371/journal.pone.0161285. eCollection 2016. PLoS One. 2016. PMID: 27548060 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources